Sarah Starling Crossan

Sarah Starling Crossan is a senior public affairs advisor in Holland & Knight's Washington, D.C., office and a member of the Public Policy & Regulation Group. Ms. Crossan's practice is centered on healthcare innovation, advising clients on regulatory and legislative policy at the intersection of care delivery, payment and emerging health technologies.

Ms. Crossan brings particular knowledge and experience in artificial intelligence (AI) and digital health policy, supporting the responsible integration of data-driven and software-based technologies into healthcare delivery and oversight frameworks. Her work also spans physician payment policy, prior authorization, care coordination and value-based payment model methodology. In addition, Ms. Crossan maintains a strong focus on rare disease policy, rural health access, and consumer-facing and over-the-counter health technologies, including prevention-oriented products such as sunscreen. She regularly engages with the Centers for Medicare & Medicaid Services (CMS), U.S. Food and Drug Administration (FDA), Assistant Secretary for Technology Policy/Office of the National Coordinator for Health Information Technology (ASTP/ONC) and U.S. Congress to help clients navigate complex policy environments while advancing patient-centered innovation.

Prior to joining Holland & Knight, Ms. Crossan spent time at a physician trade organization, where she led policy initiatives related to value-based payment and physician delivery systems. In this role, she developed and advanced comprehensive policy positions and worked closely with physician leaders, multidisciplinary stakeholders and federal agencies on complex regulatory issues.

Earlier in her career, Ms. Crossan served as professional staff on the U.S. Senate Committee on Health, Education, Labor, and Pension (HELP), where supported the development and execution of healthcare policy priorities and facilitated coordination between Congress and federal agencies. She also gained private-sector experience at a rare disease pharmaceutical company, where she supported federal government and regulatory affairs, with a focus on drug pricing policy, FDA compliance and clinical trial oversight.

Ms. Crossan is the primary author of several policy publications, including "Beyond the Discharge: Principles of Effective Care Transitions Between Settings" and "Beyond the Referral: Principles of Effective, Ongoing Primary and Specialty Care Collaboration."

In addition to her policy work, Ms. Crossan has held leadership roles supporting professional collaboration and patient advocacy. She previously served as lead staff to the Council of Subspecialty Societies and was a board member for Rare Together Tennessee, an affiliate of the National Organization for Rare Disorders (NORD).